BSE · 544759
Goldline Pharmaceutical Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹28 Cr with net profit ₹3 Cr — a 10.1% net margin, versus 7.66% the period before.
Shareholding
As of 2026-05-31
- Promoter57.29%
- Public29.74%
- FII5.16%
- DII7.81%
271 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.82× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 22.42 percentage points to 57.29% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #82 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,81,139 Cr | 38.71 | 5.76 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,840 Cr | 20.59 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,915 Cr | 19.5 | 4.94 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,247 Cr | 53.23 | 6.58 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,008 Cr | 87.79 | 18.11 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,453 Cr | 431.55 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,632 Cr | 100.56 | 2.44 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,946 Cr | 295.9 | 5.06 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,010 Cr | 538.92 | 2.03 | 1.14% | 2.3% |
| Goldline Pharmaceutical Limited(this company) | ₹36 Cr | — | 1.79 | 28.89% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashGoldline Pharmaceutical Limited is listed with a market capitalization of Rs 38 Cr. The company reported revenue of Rs 28.0557 Cr in March 2025, with a net profit of Rs 2.8342 Cr.
Positives
- +Revenue increased from Rs 19.8485 Cr in March 2023 to Rs 28.0557 Cr in March 2025.
- +Net profit increased from Rs 0.2566 Cr in March 2023 to Rs 2.8342 Cr in March 2025.
- +Earnings per share (EPS) grew from Rs 0.43 in March 2023 to Rs 4.11 in March 2025.
- +Promoter holding is 57.2915%, with no shares pledged.
Negatives
- −The profit margin is reported as 0%.
- −Debt to equity ratio is 1.22.
- −No quarterly results have been disclosed.
- −The reported dividend yield is 0%.
Financial performance
Goldline Pharmaceutical Limited's revenue increased to Rs 28.0557 Cr in March 2025 from Rs 19.8485 Cr in March 2023. Net profit also rose to Rs 2.8342 Cr in March 2025 from Rs 0.2566 Cr in March 2023. Earnings per share (EPS) grew to Rs 4.11 in March 2025 from Rs 0.43 in March 2023.
Profitability & returns
The company recorded a Return on Equity (ROE) of 28.89% and a Return on Capital Employed (ROCE) of 28.3522%. The profit margin for the latest reported period is 0%. EBITDA increased from Rs 2.0193 Cr in March 2023 to Rs 5.5819 Cr in March 2025.
Balance sheet
Goldline Pharmaceutical Limited has a book value of Rs 21. The debt-to-equity ratio is 1.22. The company does not report a dividend yield, which stands at 0%.
Ownership & pledges
Institutional holding, including DII and FII, totals 12.9688%, with DIIs holding 7.8125% and FIIs holding 5.1563%. Public shareholding is 29.7397%. There are no promoter pledges reported.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: May 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Goldline Pharmaceutical Limitedshare price & fundamentals